SPONSOR
Cabaletta Bio
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2
Conditions studied: Systemic Lupus ErythematosusLupus NephritisGeneralized Myasthenia Gravis (gMG)Pemphigus Vulgaris
Cabaletta Bio is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Systemic Lupus Erythematosus, Lupus Nephritis, Generalized Myasthenia Gravis (gMG), Pemphigus Vulgaris.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Cabaletta Bio
How many clinical trials has Cabaletta Bio sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Cabaletta Bio, of which 3 are actively recruiting participants. These trials cover conditions including Systemic Lupus Erythematosus, Lupus Nephritis, Generalized Myasthenia Gravis (gMG). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Cabaletta Bio research focus on?
Cabaletta Bio clinical trials span Systemic Lupus Erythematosus, Lupus Nephritis, Generalized Myasthenia Gravis (gMG), Pemphigus Vulgaris. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Cabaletta Bio clinical trial?
To participate in a Cabaletta Bio trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Cabaletta Bio trials with current recruitment status updated daily.
Clinical Trials by Cabaletta Bio
NCT06121297 Phase 1, Phase 2
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
NCT06359041 Phase 1, Phase 2
Recruiting
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis (gMG)
NCT04422912 Phase 1, Phase 2
Recruiting
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Pemphigus Vulgaris
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology